Results 31 to 40 of about 205,631 (301)

Circulating tumor cells isolation: The “post-EpCAM era” [PDF]

, 2015
Circulating tumor cells (CTCs) represent a submicroscopic fraction detached from a primary tumor and in transit to a secondary site. The prognostic significance of CTCs in metastatic cancer patients was demonstrated for the first time more than ten years
Gradilone, Angela, Nicolazzo, Chiara, Raimondi, Cristina   +2 more
core   +1 more source

Tc-99m-PSMA-SPECT/CT Is Superior to Tc-99m-MDP-SPECT/CT in the Staging of Prostatic Cancer with Osseous Metastases after External Beam Radiotherapy

World Journal of Nuclear Medicine, 2022
In the reported patient with advanced prostate cancer, a bone scan showed a false positive finding in thoracic vertebrae bone metastasis after external beam radiotherapy 2 months ago.
Knut Liepe, Marcel Baehr
doaj   +1 more source

Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients [PDF]

Cancer, 1997
Higher preoperative prostate specific antigen (PSA) levels are associated with higher pathologic stage and grade in patients undergoing radical prostatectomy (RP). In earlier studies, serum prostate specific membrane antigen (PSMA) elevations were associated with clinical progression and hormone-refractory carcinoma.
T H, Douglas, T O, Morgan, D G, McLeod, J W, Moul, G P, Murphy, R, Barren, I A, Sesterhenn, F K, Mostofi   +7 more
openaire   +2 more sources

Preclinical Analysis of JAA-F11, a Specific Anti-Thomsen-Friedenreich Antibody via Immunohistochemistry and In Vivo Imaging. [PDF]

, 2018
The tumor specificity of JAA-F11, a novel monoclonal antibody specific for the Thomsen-Friedenreich cancer antigen (TF-Ag-alpha linked), has been comprehensively studied by in vitro immunohistochemical (IHC) staining of human tumor and normal tissue ...
Adams, Julia, Fisk, John C, Ghazal, Diala, Jessee, Joseph, Johnson, Holly, Karacosta, Loukia G, Koury, Steven, Ludwig, Rachel, Olson, James R, Rittenhouse-Olson, Kate, Roy, Rene, Sajjad, Munawwar, Tati, Swetha, Turner, Bradley   +13 more
core   +2 more sources

T-SP1: a novel serine protease-like protein predominantly expressed in testis [PDF]

, 2008
Here, we describe a novel member in the group of membrane-anchored chymotrypsin (S1)-like serine proteases, namely testis serine protease 1 (T-SP1), as it is principally expressed in testis tissue.
Geissler, Claudia, Jochum, Marianne, Naegler, Dorit K., Nerlich, Andreas, Neth, Peter, Profanter, Birgit, Sommerhoff, Christian P.   +6 more
core   +1 more source

Incidental Discovery of Hepatocellular Carcinoma on 18F-PSMA PET CT Performed for Prostate Cancer Reassessment

Case Reports in Surgery, 2023
Prostate-specific membrane antigen positron emission tomography (PSMA PET) has been approved by the Food and Drug Administration (FDA) to identify prostate cancer in the setting of biochemical recurrence but can also identify other malignancies. 18F-PSMA
Lauren Hekman, Eva Napierkowski, Natalie C. Hartman, Jeffrey L. Ellis, Robert H. Wagner, Davide Bova, Maria M. Picken, Robert C. Flanigan   +7 more
doaj   +1 more source

Advances in targeted Alpha therapy for prostate cancer [PDF]

, 2019
BACKGROUND: Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing toxicity.
De Vincentis, G, Gerritsen, W, Gschwend, JE, Hacker, M, Lewington, V, O'Sullivan, JM, Oya, M, Pacilio, M, Parker, C, Sartor, O, Shore, N, Targeted Alpha Therapy Prostate Working Group   +11 more
core   +2 more sources

Prostate-specific membrane antigen–directed nanoparticle targeting for extreme nearfield ablation of prostate cancer cells

Tumor Biology, 2017
Almost all biological therapeutic interventions cannot overcome neoplastic heterogeneity. Physical ablation therapy is immune to tumor heterogeneity, but nearby tissue damage is the limiting factor in delivering lethal doses.
Seung S Lee, Philip JR Roche, Paresa N Giannopoulos, Elliot J Mitmaker, Michael Tamilia, Miltiadis Paliouras, Mark A Trifiro   +6 more
doaj   +1 more source

Laser-activated nanoparticles for ultrasound/photoacoustic imaging-guided prostate cancer treatment

Frontiers in Bioengineering and Biotechnology, 2023
Prostate cancer (PCa) is the most common malignant tumor in men. Prostate-specific membrane antigen (PSMA), which is overexpressed on the surface of Prostate cancer cells, may serve as a potential therapeutic target.
Linkang Xiao, Linkang Xiao, Yunfang Wu, Yunfang Wu, Junyong Dai, Junyong Dai, Weili Zhang, Yang Cao   +7 more
doaj   +1 more source

Bounce effect or local recurrence after low-dose-rate brachytherapy of the prostate? When prostate-specific membrane antigen positron emission tomography–computed tomography is false positive: a case report

Journal of Medical Case Reports
Introduction Low-dose-rate brachytherapy has been increasingly utilized as a minimally invasive treatment option in patients with low- and intermediate-risk prostate cancer.
Tamas Rozsos, Daniel S. Engeler, Hans-Peter Schmid, Christoph Schwab   +3 more
doaj   +1 more source